WHAT CAN IMMUSAFE DO?
National/Industrial Seroprevalence
- Seroprevalence is the number of individuals in a population who test positive for a specific disease.
- Recently, the number of COVID-19 cases has been on the rise, and many of these cases are asymptomatic.
- This calls for an urgent seroprevalence study to be done to identify the true number of positive individuals in relation to which domain of the N or S protein, which only ImmuSAFE® would be able to do.
National Immunosurveillance
- To monitor in real-time, long-term presence of viral antibodies within the community, and whether there is a herd immunity building.
- These would be the first step to monitor vaccine effectiveness by testing at pre and post vaccination stages.
HOW CAN IMMUSAFE ENSURE BUSINESS CONTINUITY?
Resource Planning
- By knowing the level of antibodies of each employee, employers would be able to execute effective resource planning.
- Employers will be able to anticipate or quantify the risk of infectivity among workers.
- Workers with SARS-CoV-2 antibodies can be placed at the frontline of their operations.
Containment Strategy
- The use of the MARii Tracker, a smart real-time contact tracing system, enables employers to develop a targeted containment strategy and avoid total facility shut down.
- Only affected work areas will be closed for sanitization whilst other work areas can remain operational.
Keep the Industry Going
- ImmuSAFE test kit & MARii Tracker are designed to ensure the continuity of economic activities.
- ImmuSAFE will still be relevant after the deployment of vaccines as antibody levels differ in from one individual to another.
HOW CAN ANTIBODY TEST MAKE A DIFFERENCE?
- A badminton player was cleared to play in a major tournament, despite being COVID-19 positive, after an antibody test showed she posed no danger to the tournament.
- A positive antibody test means a person has been infected with COVID-19 at some point but does not mean they are currently carrying the virus.
- https://www.reuters.com/article/health-coronavirus-badminton-thailand-idUSKBN29H0Q4
Why ImmuSAFE?
ImmuSAFE® answers the most important questions facing mankind.
Question 1 – Do I have neutralizing antibodies following infection or vaccination?
ImmuSAFE® can confirm that an individual has generated a sufficiently strong immune response to COVID-19 to confer protection.
Question 2 – Am I immune from an infection again after vaccination? If I am, how long does it last?
ImmuSAFE® can confirm the status of ongoing protection and determine whether a booster vaccine is required.
ImmuSAFE® is a full-fledged quantitative antibody test.
Data from ImmuSAFE® test enables three major conclusions to be inferred:
- There is a wide variation in antibody titres across COVID-19 infected individuals.
- There is a high degree of variation in patient-specific antibody response to the different domains of COVID-19 protein.
- Wider coverage of target epitopes leads to increased sensitivity and specificity.
ImmuSAFE® has higher sensitivity compared with single-antigen antibody tests.
- Patients selected for the study were either symptomatic or asymptomatic at the time of RT-PCR testing, with samples collected between 3 to 4 weeks after testing.
- Samples were screened on ImmuSAFE® COVID+ array.
- Independent experiments were conducted on the same convalescent COVID-19 patients on three other major leading single-antigen antibody tests.
- ImmuSAFE® has identified 6 different epitopes or functional domains of the Nucleocapsid protein, and 3 different functional domains of the Spike proten.
